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NC-ND license (http:of patients had biomarker confirmation of amyloid status. Of these, approximately 25% of mild patients
and approximately 10% ofmoderate patients were amyloid negative and, as a group, did not exhibit clin-
ical progression typical of AD. This post-hoc analysis describes a statistical surrogate for amyloid status.
Methods: Quantile regression was used to examine solanezumab treatment effects at fixed percen-
tiles of varying degrees of clinical progression, with lowest percentiles (minimal progression atypical
of AD) and higher percentiles acting as surrogates for amyloid negativity or positivity, respectively.
Results: In mild patients, solanezumab treatment effect was greater in higher percentiles of progres-
sion and less in lowest percentiles (AD-atypical). In moderate patients, solanezumab did not show
effects across most percentiles.
Discussion: Results are compatible with design of the ongoing solanezumab EXPEDITION 3 trial
that limits patients to those with mild AD dementia and evidence of amyloid pathology.
 2016 Eli Lilly and Company. Published by Elsevier Inc. on behalf of the Alzheimer’s Association.
This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/
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The amyloid cascade hypothesis proposes that Alz-
heimer’s disease (AD) is caused by an imbalance between
amyloid beta (Ab) production and clearance, ultimately giv-
ing rise to amyloid plaques in brain tissue [1,2]. Subjects
with mild cognitive impairment who are amyloid positive
are more likely to progress to dementia than those subjects
who are amyloid negative [3–6].., K.S., J.R., and R.A.D. are full-time employees and
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oped for the treatment of AD. It strongly and selectively
binds to a mid-domain of soluble Ab peptides in the periph-
ery and central nervous system [7,8]. The EXPEDITION
and EXPEDITION2 (EXP&EXP2—NCT00905372 and
NCT00904683) trials were identically designed phase 3,
multicenter, randomized, double-blind, placebo-controlled
studies of solanezumab. The primary objective of the studies
was to determine whether solanezumab treatment would
slow clinical decline versus placebo in patients with mild-
to-moderate AD dementia over 80 weeks of treatment.
Cognitive decline was measured using the Alzheimer’s Dis-
ease Assessment Scale Cognitive subscale (ADAS-Cog) [9],
and functional decline was measured using the Alzheimer’s
Disease Cooperative Study-Activities of Daily Living
(ADCS-ADL) [10].
Using these measures, the results of the two separate
studies showed solanezumab did not produce significantthe Alzheimer’s Association. This is an open access article under the CC BY-
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in patients with mild-to-moderate AD dementia [11]. How-
ever, in a prespecified pooled analyses of the mild AD sub-
group, solanezumab produced a slowing of cognitive decline
(ADAS-Cog14; least squares [LS] mean treatment difference
of 2.13 points [34%]; P 5 .001) and a slowing of functional
decline (ADCS-ADL instrumental subset; LS mean treat-
ment difference of 1.21 points [18%]; P 5 .045) relative to
placebo at 80 weeks. In the patients with moderate AD de-
mentia, solanezumab did not provide a slowing of cognitive
or functional decline [12].
All patients in EXP&EXP2 met clinical diagnostic
criteria for probable AD based on National Institute of
Neurological and Communicative Disorders and Stroke/
Alzheimer’s Disease and Related Disorders Association
criteria [13]. Under optional study addenda, baseline amy-
loid status was assessed in a subset of patients (27%), using
either cerebrospinal fluid Ab1–42 or florbetapir (
18F) imag-
ing. Baseline amyloid status was found to be negative in a
substantial fraction of patients with clinically defined
mild-to-moderate AD dementia: approximately 25% of pa-
tients with mild dementia [12] and approximately 10% of
patients with moderate dementia. Notably, patients lacking
evidence of amyloid pathology did not exhibit progressive
clinical decline typical of AD [14,15].
Because baseline amyloid status was unknown in most
patients (73%), a comparison of solanezumab and placebo
treatment effects on clinical progression in amyloid posi-
tive versus negative subjects in the full study cohort was
not possible. Accordingly, we developed a novel statistical
strategy using quantile regression to analyze treatment ef-
fect on fixed percentiles of clinical progression (minimal
clinical progression considered atypical of amyloid-
positive AD patients to a continuum of clinical progres-
sion considered more typical of amyloid-positive AD
patients).Table 1
Baseline characteristics for the mild and moderate AD study population
Baseline Characteristics




(n 5 659)* To
Age, mean (SD), years 73.3 (7.9) 73.9 (8.1) 73
Female, n (%) 362 (54.6) 346 (52.5) 7
APOE4 carriers, n (%)y 367 (59.8) 329 (55.3) 6
SOC medication at baseline, n (%) 587 (88.5) 574 (87.1) 11
Baseline efficacy measures
MMSE 22.5 (2.8) 22.5 (2.8) 22
ADAS-Cog14 29.6 (8.8) 30.1 (8.6) 29
ADCS-iADL 42.9 (9.5) 42.4 (10.0) 42
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale—Cognitive
Instrumental Activities of Daily Living Inventory; MMSE, mini mental state exam
*Number of randomized subjects. For baseline efficacy measures, the number o
with a baseline value for that measure.
yPercentage based on number of subjects with APOE4 status available (mild p
solanezumab, 326).2. Methods
Details of the EXP&EXP2 trials can be found in previous
publications [11,12]. Briefly, 1012 (EXP) and 1040 (EXP2)
patients, aged 55 years with clinically diagnosed mild or
moderate AD dementia (baseline Mini-Mental State Exam-
ination (MMSE) scores of 20–26 or 16–19, respectively),
were randomly assigned to receive placebo or solanezumab
(400 mg IV) every 4 weeks for 80 weeks. Existing standard
of care (SOC) medications for ADwere permitted (cholines-
terase inhibitors and/or memantine) provided the patients
had been treated for a minimum of 4 months and on a stable
dose for at least 2 months before randomization.
2.1. Statistical analysis
Unlike in a traditional data analysis where conventional
least squares regression is used to model the relationship be-
tween covariates and the conditional mean of the response,
quantile regression [16] models the relationship between a
set of predictor variables (e.g., treatment groups) and spe-
cific quantiles (or percentiles) of the response variable. In
a least squares regression class such as the mixed model
repeated measures (MMRM) approach used in EXP&EXP2,
mean treatment effect is merely estimated, whereas quantile
regression allows interrogation of the treatment effect on any
given quantile of response. Owing to heterogeneity of treat-
ment response, quantile regression is especially useful for
applications like EXP&EXP2, where the mean itself might
not be an adequate summary measure of treatment response;
quantile regression provides the advantage of capturing
different treatment effects at different regions of the
response distribution. This approach provides a broader
comparison of treatment effects across the observed spec-
trum of disease progression than is possible when compari-
sons are based on means or another single measure of central
tendency. At each visit, patient data in the higher percentilesModerate AD study population




(n 5 364)* Total (N5 723)
.6 (8.0) 73.7 (8.2) 73.9 (8.2) 73.8 (8.1)
08 (53.6) 210 (58.5) 234 (64.3) 444 (61.4)
96 (57.6) 201 (61.8) 199 (61.0) 400 (61.4)
61 (87.8) 333 (92.8) 337 (92.6) 670 (92.7)
.5 (2.8) 17.8 (2.5) 17.9 (2.6) 17.8 (2.6)
.9 (8.7) 42.6 (10.8) 42.1 (9.6) 42.3 (10.2)
.7 (9.7) 34.4 (11.3) 34.8 (10.8) 34.6 (11.0)
subscale (14 item); ADCS-iADL, Alzheimer’s Disease Cooperative Study
ination; SOC, standard of care.
f subjects included in each analysis varies based on the number of subjects
lacebo, 614; mild solanezumab, 595; moderate placebo, 325; and moderate
Fig. 1. Change in ADAS-Cog14 score* by treatment group (A) and change in ADCS-iADL score* by treatment group (B) from baseline to each visit time point:
patients with mild AD dementia (MMSE score, 20–26) at baseline.
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were given the surrogate biomarker-identifier of hypothe-
sized positive amyloid/AD status (“AD”). In contrast, data
in the lowest percentiles represented an atypical clinical
course and were identified with the surrogate biomarker sta-
tus of hypothesized negative amyloid/non-AD (“non-AD”).
Thus, surrogate status of “AD” or “non-AD” allowed a theo-
retical analysis of the full study cohort.
Within the pooledmild subgroup (baselineMMSEscore of
20–26) and the pooled moderate subgroup (baseline MMSE
score of 16–19) of patients from the EXP&EXP2 data set,
five fixed percentiles (quantiles: 20th, 30th, 40th, 60th, and
80th) of clinical progression were examined in this post-hoc
quantile regression analysis. Five percentiles were chosen
based on knowledge that in the subset of patients with knownamyloid status, approximately 20% were amyloid negative.
Quantile regression was applied to compare the treatment dif-
ference on the change from baseline ADAS-Cog14 and
ADCS-iADL scores at each visit time point within each fixed
percentile and compared to results from the MMRMmethod-
ology used to analyze the full intent-to-treat (ITT) patient data
set. Included in themodel, using least absolute deviationswith
covariates of study, were baseline score, treatment, AD de-
mentia severity at baseline (mild or moderate), baseline
concomitant SOC medication use, and age.3. Results
Baseline characteristics for the mild and moderate AD
study population are provided in Table 1. For the mild AD
Fig. 2. Change in ADAS-Cog14 score* by treatment group (A) and change in ADCS-iADL score* by treatment group (B) from baseline to each visit time point:
patients with moderate AD dementia (MMSE score 16–19 for moderate AD dementia) at baseline.
Y.-F. Chen et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 192-198 195study population, on average, patients were 74 years of age,
54% were female, and 58% were APOE4 carriers, with the
following mean scores on cognitive and functional tests:
MMSE: 23; ADAS-Cog14: 30; ADCS-iADL: 43. For the
moderate AD study population, on average, patients were
74 years, 61% were female, and 61% were APOE4 carriers,
with the following mean scores on cognitive and functional
tests: MMSE, 18; ADAS-Cog14, 42; and ADCS-iADL: 35.
Results of the quantile regression analyses for patients
with mild and moderate AD dementia at baseline are shown
in Fig. 1 (ADAS-Cog14, 1A; ADCS-iADL, 1B) and Fig. 2
(ADAS-Cog14, 2A; ADCS-iADL, 2B), respectively. These
results are compared to the MMRM analysis of the full
ITT cohort.Table 2 shows that in patients with mild AD dementia at
baseline, the difference in treatment effect on cognition
(ADAS-Cog14) was statistically significant for solanezumab
in the full ITT cohort (P , .001) and across all five percen-
tiles of clinical progression at week 80. The treatment differ-
ence was 2.13 points in the ITT cohort and increased from
1.06 points in the lowest quantile of progression to 2.56
points in the highest percentile of clinical progression.
Also shown in Table 2, the difference in treatment effect
on function (ADCS-iADL) was statistically significant for
solanezumab in the ITT cohort (P5 .045) and in the highest
three percentiles of clinical progression (Table 2). The treat-
ment difference was 1.21 points for the ITT cohort and
increased from 0.25 points in the lowest quantile of
Table 2
Treatment (quantile) difference in patients with mild AD dementia at baseline (solanezumab versus placebo, week 80)
Patients with mild AD dementia at baseline (n 5 1322)
ADAS-Cog14 ADCS-iADL
Sola vs PBO treatment difference P value* Sola vs PBO treatment difference P value*
All patients 2.13y .001 1.21y .045
Percentile 20th 1.06y .02 0.25y .59
30th 1.45y ,.01 0.55y .22
40th 2.10y ,.01 1.14y .04
60th 2.43y ,.01 1.72y ,.01
80th 2.56y ,.01 2.16y .05
*P values were based on Wald Test.
yValues in favor of solanezumab treatment.
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gression increased.
For ADAS-Cog14, the treatment effect in mild patients
was increasing over time at higher percentiles (60th and
80th). For ADCS-iADL, the increasing effect was seen at
the 60th percentile but was not apparent at the 80th percen-
tile (Figs. 3 and 4).
In patients with moderate AD dementia at baseline, there
were no statistically significant treatment group differences
within the ITT cohort or any percentile groups on either
cognition or function measures at week 80 (Table 3).4. Discussion
Because amyloid status was not assessed in all patients
participating in the EXP&EXP2 solanezumab clinical trials,
this post-hoc quantile regression analysis was used to
examine treatment effects across percentiles of varying de-
grees of clinical progression, with higher percentiles
(considered more typical disease progression) and lowest
percentiles (minimal disease progression) acting as hypo-
thetical surrogates for amyloid positivity (AD) or negativity
(non-AD), respectively.
In patients with mild AD dementia, treatment effect of
solanezumab was greater when clinical progression was
more typical of amyloid-positive AD patients, that is, in per-
centiles with a theoretically larger homogenous subset ofFig. 3. Effect size of solanezumab treatment over time on ADAS-Cog14 by
quantile in patients with mild AD dementia.amyloid-positive patients. When patients’ clinical progres-
sion was minimal, or atypical of amyloid-positive AD pa-
tients, solanezumab showed less effect in slowing disease
progression, suggesting that in the ITT population, the effect
of solanezumab may have been attenuated by a theoretically
higher percentage of amyloid-negative patients. In patients
with moderate AD dementia, solanezumab did not have a
statistically significant treatment effect within any clinical
progression percentile. Results reported herein based on
quantile analyses are generally consistent with those previ-
ously obtained by LS mean analyses [11,12] regarding
treatment effect of solanezumab in mild AD dementia and
lack of treatment effect in moderate AD dementia.
Although the small number of patients with known amy-
loid status precludes robust statistical analysis, we did
examine the ADAS-Cog14 change from baseline to week
80 data by quantile in patients with known amyloid status.
For the amyloid-positive patients (N5 122), the probability
of falling into the lowest percentile of clinical progression is
13.1% with patient distribution shifted to the higher quan-
tiles. Conversely, for the amyloid-negative patients
(N5 26), the probability of falling into the lowest percentile
is 42.3% with patient distribution shifted to the lower quan-
tiles. Thus, results in this small number of known amyloid-
positive and amyloid-negative patients are consistent with
use of quantile regression to provide a hypothetical surro-
gacy for amyloid status and support three hypotheses. First,Fig. 4. Effect size of solanezumab treatment over time on ADCS-iADL by
quantile in patients with mild AD dementia.
Table 3
Treatment (quantile) differences in patients with moderate AD dementia at baseline (solanezumab versus placebo, week 80)
Patients with Moderate AD dementia at baseline (n 5 723)
ADAS-Cog14 ADCS-iADL
Sola vs PBO treatment difference P value* Sola vs PBO treatment difference P value*
All patients 0.01 .991 0.51 .55
Percentile 20th 0.13 .90 0.63 .49
30th 0.30 .70 0.74 .40
40th 0.05 .95 0.73 .46
60th 0.14y .91 0.97 .33
80th 2.3 .21 0.79 .63
*P values were based on Wald test.
yValues in favor of solanezumab treatment.
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presence of amyloid-negative patients. Second, a small per-
centage of amyloid-positive patients in the lowest quantile of
progression may explain the small treatment effect demon-
strated in this group. Finally, solanezumab’s treatment effect
was not dominated by the lowest percentiles of clinical pro-
gression, theoretically composed of the highest percentage
of amyloid-negative patients, but by the highest percentiles
of clinical progression, theoretically composed of the high-
est percentage of amyloid-positive patients. Interestingly,
13.1% of amyloid-positive patients fell in the lowest percen-
tiles of clinical progression, demonstrating that on an indi-
vidual patient level, amyloid positivity does not guarantee
clinical progression with other factors, including neurofibril-
lary tangle formation, neuronal loss, age, and cognitive
reserve playing a modulatory role [6,17].
A potential limitation of this work is the assumption that
demonstrating clinical progression typical of AD can be used
as a surrogate for a biomarker-based confirmation of AD clin-
ical diagnosis and/or that clinical progression atypical of AD
can be used as a surrogate for the absence of amyloid pathol-
ogy. These assumptions could falsely ascribe AD pathology
to clinical progressors andmisclassifyADpatients with an un-
usual clinical trajectory as “non-AD”. Another limitation is
that solanezumab’s less robust effect in patients with atypical
disease progression might be due to a floor effect in the mea-
surement tools instead of a decreased effect in patients without
true AD pathology. Another limitation of this work is that the
choice of five quantiles was based on the assumption that the
percentage of patients in the full cohort who were amyloid
negative was the same as that in the known cohort. Finally,
although quantile regression produced unbiased estimates of
percentiles, the model itself had limitations, including (1) its
inability to provide robust estimates for extreme percentiles
(e.g., ,10% or .10%) when the sample size is small and
(2) some convergence issues having occurred while applying
repeated measure quantile regression fitting to these data.
Application of this statistical methodology is consistent
with the design of the ongoing solanezumab EXPEDITION3
(NCT01900665) trial being limited to patients with mild AD
dementia who have evidence of amyloid pathology. Thefindings also illustrate the potential utility of quantile regres-
sion for retrospective investigation of completed treatment
studies where universal confirmation of AD diagnosis
(e.g., positive amyloid status) was not uniformly deter-
mined. Future studies are needed to explore the validity of
the clinical course assumptions applied in this study.Acknowledgment
This study was supported by Eli Lilly and Company.RESEARCH IN CONTEXT
1. Systematic review: Authors reviewed the literature
pertaining to the amyloid cascade hypothesis and re-
sults from two solanezumab trials for mild-to-
moderate Alzheimer’s disease (AD; EXPEDITION
and EXPEDITION2). Although diagnosed with AD,
a substantial percentage of study patients were found
to be amyloid negative.
2. Interpretation: The authors used quantile regression
to examine solanezumab treatment effects at fixed
percentiles of clinical progression, with lowest per-
centiles (minimal progression atypical of AD) and
higher percentiles acting as surrogates for amyloid
negativity or positivity, respectively. In patients
with mild AD dementia, solanezumab treatment ef-
fect tended to be greater in higher percentiles. In
lowest percentiles, solanezumab showed less effect.
3. Future directions: Results are compatible with design
of the ongoing solanezumab EXPEDITION3 trial be-
ing limited to patients with mild AD dementia and
evidence of amyloid pathology. Quantile regression
may be a useful tool for retrospective investigation
of completed treatment studies where universal
confirmation of AD diagnosis was undetermined.
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